Introduction
The thyroid controls several metabolic pathways through the synthesis and release of thyroxine (T4) and its active derivative triiodothyroxine (T3), which binds to nuclear receptors to regulate gene expression and impact growth, development, and metabolism. 1 Consistent with its critical role in muscle, bone, central nervous system, and heart physiology, abnormal thyroid function can lead to hyperthyroidism, hypothyroidism, and related childhood neuropsychological abnormalities including severe cretinism. 2 The key regulator of thyroid function is thyroid-stimulating hormone (TSH). Secreted by the pituitary, TSH interacts with the TSH receptor (TSHR) on thyroid cells to upregulate cyclic AMP (cAMP) and induce Ca 2þ release and activation of phosphoinositol. 3 These effectors then lead to the expression of downstream gene targets, culminating with pinocytosis of thyroglobulin and the release of T4 and T3, enhanced iodide uptake, and, on a longer time scale, growth and differentiation of thyroid follicular cells. TSH levels are themselves controlled in several ways. TSH production is promoted by thyrotropin-releasing hormone (TRH) and inhibited by somatostatin, both produced by the hypothalamus. 4, 5 In addition, negative-feedback control on hypothalamic release of TRH and pituitary release of TSH is exerted by the blood levels of thyroid hormone. When the levels of T3 and T4 are low, the production of TRH and TSH increases, and conversely, when T3 and T4 levels are high, TRH and TSH production decreases. 6 Serum TSH concentrations are a sensitive indicator of thyroid function. High and low TSH levels reflect hypoand hyperfunction of the thyroid gland, respectively. However, even within the normal range, TSH is a sensitive measure of thyroid function, and normal (euthyroid) individuals show narrow individual variation, suggesting that the thyroid-hormone axis is tightly regulated. TSH levels are genetically regulated and~40% heritable in several populations; however, specific gene variants that influence TSH levels are not known. [7] [8] [9] To identify specific possible genetic factors affecting TSH levels and thyroid function, we studied a Sardinian cohort 7 in whom the founder-population structure can simplify genetic analyses of complex traits and diseases. This has recently facilitated the finding of genes associated with susceptibility to asthma, 10 obesity-related traits, 11 uric acid, 12 lipid levels, 13 height, 14 and severity of b-thalassemia. 15 Here we report analyses that point to common variants in PDE8B [MIM 603390], 16 a gene that encodes a high-affinity cAMP-specific phosphodiesterase (PDE), as genetic modulators of TSH levels. [MIM 600998], 21 among genes in a focused analysis of 24
candidates for involvement in the dynamic regulation of thyroid function. Overall, our results suggest that PDE8B, by affecting cAMP concentrations in the thyroid, may alter thyroid-hormone levels in the serum and affect TSH release from the pituitary. PDE8B variants thus modulate thyroid physiology and may affect the course of thyroid disease.
Material and Methods

Sample Description
We recruited and phenotyped 6,148 individuals, males and females, ages 14-102 yr, from a cluster of four towns in the Lanusei Valley of Sardinia. 7 During physical examination, a blood sample was collected from each individual and divided into two aliquots. One aliquot was used for DNA extraction and the other to characterize several blood phenotypes, including evaluation of serum TSH levels. TSH was measured with the Siemens TSH assay (Immulite 2000) according to the manufacturer's instruction. The method is a solid-phase, chemiluminescent, competitive analog immunoassay and has analytical sensitivity of 0.004 mIU/ml and upper limit of 75 mIU/ml of TSH. This method is a third-generation TSH assay and has a sensitivity and detection range comparable to the methods used to evaluate TSH levels in the other cohorts studied (see below). Thyroid ultrasound examination was also performed on all the individuals enrolled in the study, with a portable real-time instrument using a 7.5-MHz linear transducer. Subjects were examined in the supine position, with neck hyperextended, by transverse and longitudinal scans to evaluate overall thyroid size and echotexture. Thyroid volume was calculated for each lobe according to the ellipsoid formula (length 3 breadth 3 width 3 0.523) (normal range 10.7 5 4.6 ml to 11.5 5 3 ml). Goiter was scored when the total thyroid volume was above the mean thyroid volume. Reduction of thyroid volume associated with diffuse alteration of echotexture indicative of chronic thyropathies was also detected. Presence, structure, size, and vascularization of nodules were determined by ultrasound and color-Doppler sonography. Records of self-reported thyroid disease status (i.e., autoimmune thyroiditis, thyroid cancer, partial or total thyrectomy) and hormonereplacement therapy were available for all subjects.
Each participant signed an informed consent form. All study methods have been approved by the local ethics committee.
GWAS Genotyping
During the study, we genotyped 4,305 individuals selected from the whole sample to represent the largest available families, regardless of their phenotypic values. Specifically, 1,412 were genotyped with the 500K Affymetrix Mapping Array Set and 3,329 with the 10K Mapping Array Set, with 436 individuals genotyped with both arrays. This genotyping strategy allowed us to examine the majority of our cohort in a cost-effective manner because genotypes for the SNPs that passed quality-control checks could be propagated through the pedigree via imputation.
11,22 TSH measurements were available for 4,300 individuals among the 4,305 genotyped. A total of 362,129 SNPs passed initial quality-control checks 11 and were tested for association with TSH levels with an additive model. Further details of the strategy for imputation and data analysis are given in the Statistical Analysis section below. An additional 1,236 individuals were genotyped with the 10K Mapping Array Set but were not included in the genomewide association scan (GWAS) because no close relatives were typed with the 500K Mapping Array Set. These individuals were, however, included in the fine-mapping analysis.
Replication and Fine Mapping
We designed a ParAllele Custom Chip (from Affymetrix) to replicate and refine the regions associated with TSH levels as well as other traits studied in the SardiNIA Project. 7, 15 Specifically, for the locus associated with TSH levels, we included 70 markers that were chosen as SNP tags of markers falling in the coding regions of the PDE8B gene and that also passed reliability criteria in the design phase. SNP rs6885099 showed the strongest association with TSH levels in an initial analysis performed on a subset of phenotyped individuals and was thus included in the custom chip (instead of rs4704397, which ranked second in the initial analysis). Genotyping was performed in Sardinian individuals selected for replication or for fine-mapping efforts. In particular, for replication, we genotyped and analyzed 1,858 individuals from the Sardi-NIA cohort (stage 2), who were unrelated (kinship coefficient ¼ 0) to the individuals in stage 1.
For fine mapping, we genotyped a subset of 634 individuals from stages 1 and 2 including 100 couples (mothers and fathers) already typed with the 500K Mapping Array Set and 434 individuals representing children from the larger sibships.
InCHIANTI
The InCHIANTI study is an ongoing epidemiological study in two Italian towns in the Chianti area (Tuscany). A detailed description of the study design and data-collection methods has been published. 17, 23 Plasma TSH levels were measured with commercial kits (Vitros TSH Reagent, Ortho-Clinical Diagnostics, Johnson & Johnson Medical S.p.A Section) by chemiluminescent assay. The assay has an analytical sensitivity of 0.003 mIU/ml. The intra-assay coefficients of variation (CVs) were 3.9% to 5.3% over the range 0.06-80.11 mIU/ml. SNP rs4704397 was genotyped in this cohort by TaqMan Single SNP genotyping assays (Applied Biosystems).
Old Order Amish
The Old Order Amish (OOA) study participants reported here were from ongoing studies of cardiovascular disease and longevity; none were ascertained on the basis of thyroid disease. 18, 24 A total of 1,136 individuals from these two studies had serum TSH measured by Quest Diagnostics (Nichols Institute) with a standardized third-generation assay and were previously genotyped for rs4704397 with the 500K Affymetrix Mapping Array Set.
Statistical Analysis
To evaluate the additive effect of each marker, we fitted a simple regression model and used a variance-component approach to account for correlation between different observed phenotypes within each family. Gender, age, and age squared were included as covariates in all analyses, and the trait was normalized with quantile normalization to avoid inflation of type I error rates. For individuals genotyped with a sparse map, we used a modified version of the Lander-Green algorithm 25, 26 to estimate IBD sharing at the location of the SNPs being tested and identify stretches of haplotype shared with close relatives who were genotyped at higher density and probabilistically infer missing genotypes. 22 In brief, in the statistical approach to estimate each genotype, we first calculated the likelihood of the observed genotype data. Then, we assigned each missing genotype to a specific value and updated the likelihood pedigree. The ratio of the two likelihoods gave a posterior probability for the proposed genotype conditional on all available data. Furthermore, instead of assigning the most likely genotype, we estimated an expected genotype score, representing the expected number of copies of a reference allele (a fractional number between 0 and 2), which allowed us to partially account for uncertainty in genotype assignment. The genotype scores were then used in a variance-component-based association test as described. 22 Because of computational constraints, we divided large pedigrees into subunits with ''bit-complexity'' 26 of 19 or less (typically, 20-25 individuals) before analysis. False-discovery rates (FDRs) were calculated with R's p.adjust() procedure via the method of Benjamini and Hochberg. 27 In SardiNIA stage 2 replication and in InCHIANTI samples, association with TSH was tested as in the SardiNIA GWA sample, except that no imputation was required. Association analyses to test for additive effects in the Old Order Amish sample were carried out under a variance-component framework implemented in SOLAR; 28 these analyses modeled the effect of genotype on TSH levels while adjusting for the effects of age and sex and accounting for a background polygenic contribution to variation in TSH levels occurring because of the relationships existing among the examined individuals. 29 The choice of SOLAR was based on the presence of larger pedigrees in the OOA families and the lack of a requirement for genotype imputation in these samples. For fine mapping in the SardiNIA sample, we merged all available genotypes from all the platforms (500K Mapping Array Set, 10K Mapping Array Set, ParAllele custom chip) for a total of 6,062 nonoverlapping individuals. Because fewer markers were analyzed than in the GWAS, larger pedigrees were divided into units of bit-complexity of 21 or less before analysis. Missing genotypes for individuals typed with only one platform were inferred with the same approach used in the GWA analysis. We then evaluated the additive effect of each marker by using allele dosages as above.
Results
Genome-wide Association Scan for TSH Levels in Sardinians
Genome-wide association analyses were carried out in 4,300 volunteers characterized for circulating TSH levels (see Material and Methods). 7, 11 Analyses revealed three SNPs with genome-wide significant association at a single chromosome 5 locus (p < 10 À10 , see Table 1 and Figure 1 ).
These SNPs and three other SNPs among our top 25 signals lie in intron 1 or upstream of the PDE8B gene (Table 1 and Figure 2) . 16 Their locations and linkage-disequilibrium strongest association, rs4704397, explains 2.3% of the variance of TSH levels. Each copy of the minor A allele is associated with an average increase of 0.13 mIU/ml in TSH levels.
Replication of the Association of rs4704397/PDE8B in Other Populations
To confirm the association of rs4704397 with TSH levels, we analyzed two additional cohorts, one comprising 1,164 Tuscan subjects from the genetically distinct In-CHIANTI study population 17, 23 and the second 1,136 individuals from the founder population of the Old Order Amish. 18, 24 We also analyzed a replication cohort of 1,858
individuals enrolled in the SardiNIA study but unrelated to the first group (designated here as stage 2 analysis). The features of these cohorts are given in Table 2 , and the results of association are summarized in Table 3 . Analysis revealed that SNP rs4704397 or its surrogate rs6885099 was associated with the TSH trait in all the cohorts tested, with the same direction of effect as observed in our original sample (Table 3) . Notably, the effect size in the replication samples was about half that observed in the initial GWAS (0.25 versus 0.12). This may be due to less accurate estimates of effect size as a result of reduction in sample size and consequent decrease of statistical power, or it may reflect the ''winner's curse'' phenomenon, where effect-size estimates for markers that reach statistical significance may be inflated. The combined p value from stage 2 analyses in the three cohorts was highly significant (p ¼ 2.0 3 10 À10 ), leading to a cumulative-association p value of 1.9 3 10 À20 . Table 3 also summarizes the distribution of the TSH levels for each genotype class for the SNP rs4704397 and shows that in all the samples, individuals carrying at least one copy of the minor A allele have higher circulating levels of TSH than those homozygous for the major G allele, showing a trend for an additive model. In the Amish sample, the mean TSH value for individuals with the A/G genotype appears slightly higher than that observed for the A/A subjects. This could result from the different frequency of the rare A allele and the lower frequency of the A/A genotype in the Amish compared with the other cohorts; this lower frequency would yield less accurate mean-value estimates for this genotype class compared to values in the other cohorts.
We also repeated association analyses in all cohorts after stratifying subjects into two groups, one group including individuals with TSH levels in the normal range (0.4-4.0 mIU/ml), with no reported history of thyroid disease, and not taking thyroid medications (group 1, Table 4 ), and the other group including the remaining subjects (group 2). The results confirmed the association of rs4704397 in both the unaffected and the thyroid-affected individuals ( Table 4) . Because of the reduction in sample size, the p value was lower in the two subsets, but the effect size of the associated A allele was larger in group 2 individuals (in all but the OOA cohort), suggesting a potential involvement of PDE8B activity in the course of thyroid disease. Further analysis in a larger subgroup of thyroid-affected Sardinian subjects, including all the individuals from group 2 as well as individuals with nodules and goiters (formerly in group 1), showed stronger association when compared to the remaining subjects, again confirming a larger effect size of the A allele in thyroid-affected individuals (see Table S1 available online). Despite the consistently larger effect in thyroid-affected individuals in several studies, this difference does not reach statistical significance (Cochran's Q statistic 32 
consequently, larger studies will be necessary to test this hypothesis further. Association analysis of rs4704397 in males and females did not suggest gender-specific effects (Table S2) . Signals for other loci that did not reach genome-wide significance ( as PDE8B), some further testing was performed. SNP rs657152 did not replicate in the Amish or InCHIANTI cohorts, whereas rs2983521 was replicated in InCHIANTI, with a one-sided p value of 0.048, but was not supported in the Amish samples (data not shown). Thus, its involvement in the variability of TSH remains suggestive, requiring study in additional cohorts.
Fine Mapping in the PDE8B Locus To identify possible coding and/or functional variants involved in the regulation of PDE8B activity in the context of TSH variation, we genotyped 70 additional SNPs falling in the PDE8B gene or in the neighboring 5 kb upstream and downstream regions in 2,492 Sardinians. We analyzed all the available markers (39 from the GWAS and 70 from the custom chip) in the individuals genotyped with at least one platform and for whom TSH values were available (n ¼ 6,062). As shown in Figure 2C and Table S3 , the strongest association signals all pointed to intron 1, common to all five PDE8B isoforms, in which ten significant SNPs were located. The top three SNPs confirmed the previous top three markers detected in the GWAS, though with a shifted rank order (rs6885099, p ¼ 1.69 3 10 À14 ; rs4704397, p ¼ 1.01 3 10 À12 ; rs2046045, p ¼ 3.76 3 10 À12 ). Several of the SNPs show linkage disequilibrium (r 2 > 0.5) with SNPs in neighboring regions (Figures 2A and 2B) , suggesting that the functional variant(s) may lie outside of intron 1. However, it seems likely that they will reside in a noncoding sequence, because sequence analysis of all the PDE8B exons in 20 subjects homozygous for the rare and 20 for the common alleles of the top two associated SNPs, rs4704397 and rs6885099, did not reveal any coding variants (data not shown). In addition to intron 1, we also found evidence of association for two new SNPs within intron 10 of PDE8B1. The functional relevance of these variants remains to be elucidated. Further studies, including largescale resequencing and molecular analyses, will be necessary to verify the effects of the associated variants on the regulation of the TSH levels.
Association Analysis of Candidate Genes with TSH Levels
Our GWA analysis implicated PDE8B as the only gene with a significant effect on variation of TSH. Because PDE8B variants contribute only 2.3% of TSH variation, which represents a small part of the total genetic component of the trait (~40%), we expected other genes to contribute to TSH levels, albeit with smaller effects. To begin to look for such genes, we carried out in the SardiNIA cohort a subanalysis focusing on candidate genes, where a less stringent significance threshold would increase power. We selected 24 candidate genes on the basis of their reported function in cAMP metabolism, TSH signaling, and the regulation of thyroid function. No linkage and association studies showing a correlation with TSH levels had previously been performed for any of these candidates. When markers falling in the candidates and already genotyped in the GWAS were tested for their association with TSH levels, as expected none reached genome-wide significant association (Table 5) . However, substantive evidence of association was detected for some genes involved in the biological activity and negative feedback of thyroid hormone (THRB), 20 
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We compared association results in two subgroups. Group 1 identifies healthy subjects and consists of individuals with TSH levels in the normal range of 0.4-4 mIU/dl and with no history of thyroid disease (thyroid medications, thyroid cancer, surgery, or autoimmune thyroiditis). Group 2 consists of the remaining subjects. a The effect size refers to the minor allele frequency (MAF) allele; it is measured in standard-deviation units and is estimated as the b coefficient of the regression model when the normalized trait is used (e.g., an effect size of 1.0 implies that each additional copy of the allele increases trait values by 1.0 standard deviation). b Results are for rs6885099, in strong LD (r 2 ¼ 0.98) with rs4704397, which was not genotyped (see Materials and Methods). c Thryoid autoimmunity and thyroid cancer information were not reported in the InCHIANTI database. Old Older Amish database did not contain any information regarding thyroid disease, so only out-of-range TSH values and history of taking thyroid-hormone therapy were considered to define group 2. d Old Older Amish database did not contain information regarding thyroid disease, so only out-of-range TSH values and history of taking thyroid-hormone therapy were considered to define group 2.
focused analysis on the basis of their cAMP specificity and reported expression in thyroid tissues. We have calculated the corresponding FDRs 27 by taking into account all the 503 SNPs tested in the candidate-gene analysis. Notably, by this criterion, the q value for SNPs falling in the THRB and GNAQ genes reached the significant threshold of 0.05 (q ¼ 0.036 and q ¼ 0.050, respectively), suggesting a possible involvement in the variability of TSH levels.
Discussion
The PDE8B gene, encoding a high-affinity cAMP phosphodiesterase, 37 is inferred to modulate circulating TSH levels in three independent populations, with a combined p value of 1.9 3 10 À20 . Of the five characterized PDE8B isoforms, the major isoform PDE8B1 and minor isoforms PDE8B2 and PDE8B3 are abundantly expressed in the thyroid. 16, 38 Because PDE8B is undetectable in the pituitary, 39 we infer it to act primarily in the thyroid to catalyze the hydrolysis and inactivation of cAMP after TSH signaling. PDE8B could then influence TSH levels by feedback from an effect on the generation of T4 and T3 in the thyroid, in line with reports that both thyroglobulin endocytosis and thyroid-hormone secretion are stimulated by TSH via a cAMP-dependent pathway. 3 Although no signals other than PDE8B reached genomewide significance (Table 5) , several candidate genes showed suggestive evidence of association. These included two other cAMP-specific phosphodiesterases, PDE4D, 34, 35 and, at a much lower level of significance, PDE7B. 36 It is relevant that the cAMP-specific PDE4 family has also been suggested to be involved in modulating the cAMP signal after TSH stimulation of thyrocytes. 34 Furthermore, some evidence for association was also detected in our GWAS in PDE10A, a phosphodiesterase with dual specificity for cyclic nucleotides and stimulated by cAMP. 19 Analyses using differential inhibition or transfection of the range of phosphodiesterases and their variants in thyrocytes should help to determine their contribution to cAMP levels. As for other genes previously implicated in TSH homeostasis, the thyroid-hormone receptor, b (THRB) 20 and several G protein genes-in particular, GNAQ, 21 previously reported to be required for TSH-induced thyroid-hormone synthesis and release-implicated in the signal transduction of hormone receptors, also showed suggestive The first column indicates the name of a previously identified candidate gene. The second column indicates the number of SNPs in our Affymetrix arrays that are within 5 5 kb of the gene. The next column indicates the number of HapMap SNPs within 5 5 kb of the gene and the proportion of these that are covered at r 2 ¼ 0.50 or r 2 ¼ 0.80 by SNPs in the Affymetrix arrays. The remaining columns indicate the SNP that showed strongest association in our analysis, the p value, the tested allele and its frequency, and the estimated additive effect in standard-deviation units. Association was tested either with intragenic SNPs or with the best available tag for intragenic SNPs (r 2 > 0.5). Shown in bold are candidate genes with SNPs reaching p values % 0.05. a The effect size refers to the MAF allele; it is measured in standard-deviation units and is estimated as the b coefficient of the regression model when the normalized trait is used (e.g., an effect size of 1.0 implies that each additional copy of the allele increases trait values by 1.0 standard deviation).
association signals (Table 5) . Finally, some evidence of association was also noticed in two thyroid-specific genes, thyroglobulin (TG) and thyroid-stimulating hormone receptor (TSHR), 33 and in POU class 1 homeobox 1 (POU1F1 [MIM 173110]), 40 a gene expressed in the pituitary and important for the regulation of a number of pituitary hormones. We infer that much of the TSH-level variance that subtly affects normal and possibly pathological states seems to be exerted at the level of cAMP degradation. It is possible that genomic PDE8B mutations could be responsible for certain thyroid diseases-for example, for increased serum TSH occasionally observed in individuals with no evidence of thyroid autoimmunity or loss-of-function mutations in the thyroid-hormone-or TSH-receptor genes. 41 Because PDE8B has the highest affinity for cAMP of any known phosphodiesterase, 37 the enzyme would be active even at low concentrations of cAMP, and a change in its level or activity could have an especially marked effect on TSH signaling. Consistent with this notion, a mutation in PDE8B that leads to elevated cAMP levels has now been identified in a case of adrenal hyperplasia in Cushing syndrome (AIMAH [MIM 219080]). 42 Increased cAMP-degrading PDE8B activity has also been detected in autonomous thyroid adenomas, where it may represent a compensatory mechanism opposing the constitutive activation of the cAMP pathway. 34 Other reports have noted PDE8B upregulation in Alzheimer's disease (AD [MIM 104300]) brain 43 and pituitary adenomas, 39 as well as involvement in a model of modified insulin secretion. 44 PDE family members have increasingly been implicated in the pathogenesis of a number of other diseases, including cardiovascular disorders, renal failure, 45 adrenocortical hyperplasia, 42, 46 and a wide variety of inflammatory pathologies. 47 Selective isoform-specific PDE inhibitors are already employed to treat several diseases, and thus PDE8B may provide a pharmaceutical target for certain thyroid pathologies.
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